S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
NASDAQ:PRTK

Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

$2.54
+0.42 (+19.81%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.38
$2.80
50-Day Range
$1.37
$2.54
52-Week Range
$1.29
$3.65
Volume
5.80 million shs
Average Volume
570,887 shs
Market Capitalization
$145.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
687.4% Upside
$20.00 Price Target
Short Interest
Bearish
7.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
1.03mentions of Paratek Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$687,106 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.97) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

914th out of 1,004 stocks

Pharmaceutical Preparations Industry

448th out of 489 stocks


PRTK stock logo

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Stock News Headlines

Adam Mesh: “This Strategy Saved My Trading Career”
Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. pixel
Q4 2022 Paratek Pharmaceuticals Inc Earnings Call
Adam Mesh: “This Strategy Saved My Trading Career”
Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. pixel
Why Paratek Pharmaceuticals Stock Is Plunging Today
Paratek Pharmaceuticals Earnings Preview
See More Headlines
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings
11/08/2021
Today
3/31/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
207
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+292.4%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-63,570,000.00
Pretax Margin
-39.63%

Debt

Sales & Book Value

Annual Sales
$160.27 million
Book Value
($3.08) per share

Miscellaneous

Free Float
52,684,000
Market Cap
$145.93 million
Optionable
Optionable
Beta
1.52

Social Links


Key Executives

  • Evan LohEvan Loh
    Chief Executive Officer & Director
  • Adam WoodrowAdam Woodrow
    President & Chief Commercial Officer
  • Sarah Higgins
    VP, Chief Financial & Accounting Officer
  • Raj Padmanabhan
    Vice President-Information Technology
  • Paul McGovern
    Vice President-Clinical & Medical Affairs













PRTK Stock - Frequently Asked Questions

What is Paratek Pharmaceuticals' stock price forecast for 2023?

0 equities research analysts have issued 1 year price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $10.00 to $30.00. On average, they predict the company's share price to reach $20.00 in the next year. This suggests a possible upside of 684.8% from the stock's current price.
View analysts price targets for PRTK
or view top-rated stocks among Wall Street analysts.

How have PRTK shares performed in 2023?

Paratek Pharmaceuticals' stock was trading at $1.87 at the start of the year. Since then, PRTK stock has increased by 36.3% and is now trading at $2.5485.
View the best growth stocks for 2023 here
.

When is Paratek Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PRTK earnings forecast
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analysts' expectations of $22.98 million. During the same quarter in the prior year, the company posted ($0.46) EPS.

What ETFs hold Paratek Pharmaceuticals' stock?

ETFs with the largest weight of Paratek Pharmaceuticals (NASDAQ:PRTK) stock in their portfolio include AltShares Event-Driven ET (EVNT) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $143.00 million-$158.00 million, compared to the consensus revenue estimate of $232.02 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?
What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (7.48%), General American Investors Co. Inc. (3.39%), Millennium Management LLC (1.02%), Geode Capital Management LLC (0.84%), CM Management LLC (0.62%) and Renaissance Technologies LLC (0.44%). Insiders that own company stock include Adam Woodrow, Evan Loh, James D Dondero, Jeffrey Stein, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends
.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $2.55.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $145.93 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

The company employs 207 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 3/31/2023 by MarketBeat.com Staff